Intec Pharma Ltd (NTEC) Given a $10.00 Price Target at Roth Capital
Intec Pharma Ltd (NASDAQ:NTEC) has been assigned a $10.00 target price by Roth Capital in a research report issued to clients and investors on Thursday. The firm currently has a “buy” rating on the biotechnology company’s stock. Roth Capital’s price objective indicates a potential upside of 85.19% from the company’s previous close.
Several other research firms also recently commented on NTEC. Zacks Investment Research downgraded shares of Intec Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, May 24th. ValuEngine cut shares of Intec Pharma from a “hold” rating to a “sell” rating in a research report on Friday, June 9th. Finally, Maxim Group set a $9.00 price objective on shares of Intec Pharma and gave the stock a “buy” rating in a research report on Wednesday, May 24th.
Shares of Intec Pharma (NTEC) traded down 0.92% during mid-day trading on Thursday, hitting $5.40. The stock had a trading volume of 2,246 shares. Intec Pharma has a 12 month low of $4.20 and a 12 month high of $6.36. The stock’s 50-day moving average is $5.49 and its 200 day moving average is $5.25. The firm’s market cap is $74.18 million.
About Intec Pharma
Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.
Receive News & Ratings for Intec Pharma Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma Ltd and related companies with MarketBeat.com's FREE daily email newsletter.